Study: Medtronic stent safer than competitor
Published: Tuesday, September 22, 2009 at 4:30 p.m.
Last Modified: Tuesday, September 22, 2009 at 4:30 p.m.
Medtronic Inc. said a new clinical study shows its Endeavor drug-coated stent, which was developed in Santa Rosa, is safer than a leading competitor.
The three-year study of more than 1,500 patients at 80 U.S. sites compared Endeavor with Boston Scientific’s Taxus drug-coated stent.
Stents are metal mesh tubes implanted in heart patients’ arteries to keep their blood flowing. Endeavor and Taxus are coated with special drugs to keep arteries from re-clogging. But drug-coated stents have been linked to blood clotting, heart attacks and even death in a small number of cases.
The study shows patients treated with Endeavor have a much smaller risk of blood clotting, heart attack or cardiac death than those treated with Taxus stents, according to Medtronic.
Minneapolis-based Medtronic has about 840 employees at its cardiovascular unit in Santa Rosa.
All rights reserved. This copyrighted material may not be re-published without permission. Links are encouraged.
Comments are currently unavailable on this article